| Gene symbol | APOB | Synonyms | FCHL2, FLDB, LDLCQ4, apoB-100, apoB-48 | Type of gene | protein-coding |
| Chromosome | 2 | Map location | 2p24.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PertOrg | ||||
| Description | apolipoprotein B | ||||
| GTO ID | GTC1376 |
| Trial ID | NCT01299298 |
| Disease | Familial Hypercholesterolemia |
| Altered gene | APOB |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | ISIS 301012|mipomersen sodium|Kynamro |
| Location approved | US, Mexico, Argentina, South Korea |
| Phase | Phase1 |
| Recruitment status | Completed |
| Title | A Prospective, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Doses of Mipomersen Administered Subcutaneously to Japanese Healthy Subjects |
| Year | 2011 |
| Country | Germany |
| Company sponsor | Kastle Therapeutics, LLC |
| Other ID(s) | MIPO3700710|2010-021948-18 |
| Vector information | |||
|
|||
| Cohort1: mipomersen_dose level 1 | |||||||
|
|||||||
| Cohort2: mipomersen_dose level 2 | |||||||
|
|||||||
| Cohort3: mipomersen_dose level 3 | |||||||
|
|||||||
| Cohort4: Placebo | |||||||
|
|||||||